These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 8733693)
1. Serum HLA class I antigen levels in allogeneic bone marrow transplantation: a possible marker of acute GVHD. Puppo F; Brenci S; Ghio M; Bignardi D; Contini P; Bacigalupo A; Van Lint MT; Scudeletti M; Ferrone S; Indiveri F Bone Marrow Transplant; 1996 May; 17(5):753-8. PubMed ID: 8733693 [TBL] [Abstract][Full Text] [Related]
2. Elevated serum HLA class I levels coincide with acute and chronic graft-versus-host disease. Liem LM; Koelman CA; Doxiadis II; van Houwelingen JC; Goulmy E; Claas FH Bone Marrow Transplant; 1997 Aug; 20(3):227-34. PubMed ID: 9257891 [TBL] [Abstract][Full Text] [Related]
3. Soluble interleukin 2 receptors in patients after bone marrow transplantation. Siegert W; Josimovic-Alasevic O; Schwerdtfeger R; Baurmann H; Schmidt CA; Musch R; Schmid HJ; Hartmann R; Henze G; Huhn D Bone Marrow Transplant; 1990 Aug; 6(2):97-101. PubMed ID: 2207458 [TBL] [Abstract][Full Text] [Related]
4. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation. Russell CA Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093 [TBL] [Abstract][Full Text] [Related]
5. Low incidence of acute GVHD in patients transplanted with marrow from HLA-A,B,DR-compatible unrelated donors among Japanese. Morishima Y; Kodera Y; Hirabayashi N; Tanimoto M; Matsuyama T; Horibe K; Ohta H; Mizuno S; Morishita Y; Yamauchi T Bone Marrow Transplant; 1995 Feb; 15(2):235-9. PubMed ID: 7773212 [TBL] [Abstract][Full Text] [Related]
6. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736 [TBL] [Abstract][Full Text] [Related]
7. Measurement of recipient-specific alloreactivity: is GVHD predictable? Theobald M; Bunjes D; Nierle T; Arnold R; Heimpel H Bone Marrow Transplant; 1993; 12 Suppl 3():S18-23. PubMed ID: 8124251 [TBL] [Abstract][Full Text] [Related]
8. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Passweg JR; Tiberghien P; Cahn JY; Vowels MR; Camitta BM; Gale RP; Herzig RH; Hoelzer D; Horowitz MM; Ifrah N; Klein JP; Marks DI; Ramsay NK; Rowlings PA; Weisdorf DJ; Zhang MJ; Barrett AJ Bone Marrow Transplant; 1998 Jan; 21(2):153-8. PubMed ID: 9489632 [TBL] [Abstract][Full Text] [Related]
9. Correlation of low histidine rich glycoprotein plasma levels with the occurrence of acute graft-versus-host disease after allogeneic bone marrow transplantation. Mauz-Körholz C; Körholz D; Burdach S J Lab Clin Med; 1995 Aug; 126(2):144-50. PubMed ID: 7636387 [TBL] [Abstract][Full Text] [Related]
10. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Mutis T; Gillespie G; Schrama E; Falkenburg JH; Moss P; Goulmy E Nat Med; 1999 Jul; 5(7):839-42. PubMed ID: 10395333 [TBL] [Abstract][Full Text] [Related]
11. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Hägglund H; Boström L; Remberger M; Ljungman P; Nilsson B; Ringdén O Bone Marrow Transplant; 1995 Dec; 16(6):747-53. PubMed ID: 8750264 [TBL] [Abstract][Full Text] [Related]
12. [Determination of soluble HLA class I molecules in children in bone marrow transplantation]. Sedivá A; Starý J; Hromadníková I; Skalická A; Ghio M Cas Lek Cesk; 2000 Oct; 139(20):630-4. PubMed ID: 11192758 [TBL] [Abstract][Full Text] [Related]
13. The predictive value of helper T lymphocyte precursor frequencies for graft-versus-host disease and graft-versus-leukaemia effects in allogeneic bone marrow transplantation. Russell CA; Heilmann C; Madsen HO; Vindeløv LL Bone Marrow Transplant; 2001 May; 27(9):949-58. PubMed ID: 11436105 [TBL] [Abstract][Full Text] [Related]
14. [Preliminary study of HLA haplotype matched and T-cell undepleted allogeneic bone marrow transplantation for treatment of leukemia]. Ji S; Chen H; Wang H Zhonghua Xue Ye Xue Za Zhi; 2001 Aug; 22(8):408-10. PubMed ID: 11718090 [TBL] [Abstract][Full Text] [Related]
15. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran. Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149 [TBL] [Abstract][Full Text] [Related]
16. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290 [TBL] [Abstract][Full Text] [Related]
17. Primary human keratinocytes as targets in predicting acute graft-versus-host disease following HLA-identical bone marrow transplantation. van Dijk AM; Kessler FL; Verdonck LF; Stadhouders-Keet SA; van Lier RA; de Gast GC; Otten HG Br J Haematol; 2000 Dec; 111(3):791-6. PubMed ID: 11122139 [TBL] [Abstract][Full Text] [Related]
18. Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM). Bacigalupo A; Oneto R; Bruno B; Lamparelli T; Gualandi F; Bregante S; Raiola AM; Di Grazia C; Dominietto A; Lombardi A; Frassoni F; Van Lint MT Bone Marrow Transplant; 2001 Dec; 28(11):1041-5. PubMed ID: 11781614 [TBL] [Abstract][Full Text] [Related]